Receptor tyrosine kinases (RTK) play a significant role in the signal transduction of normal, and malignant hematopoietic cells. We have previously shown that Axl, a novel RTK, is mainly expressed in leukemias of myeloid origin, and that its expression may be associated with cells of monocytic origin. Since expression of certain RTKs in cancer may be associated with different biology and survival, we investigated whether the expression of Axl is associated with clinical characteristics and survival in acute myeloid leukemia (AML). RNA from 54 patients with AML treated in a cooperative group trial was analyzed in a retrospective and blinded manner using a semi-quantitative reverse transcriptase polymerase chain reaction-based assay with primers specific for the Axl gene. Axl expression was found in 19 out of the 54 cases (35%). Axl expression was not detected more frequently in patients of older age, specific FAB categories, or cases with extramedullary disease. However, there existed a correlation between Axl and bcl-2 expression levels. AML cells with high bcl-2 expression showed higher Axl expression (r = 0.32; P = 0.02), and furthermore, Axl transcript numbers were also higher in AML with high CD34 expression (n = 38, r = 0.42; P = 0.008). No significant difference between leukemias expressing and not expressing Axl was found with regard to complete remission rate. However, quantitative Axl expression was associated with worse progression-free and overall survival. Higher Axl levels had worse prognosis for progression-free (␤: 0.68, s.e.: 0.28, P = 0.015) and overall survival (␤: 0.61, s.e.: 0.31, P = 0.05) using multivariate Cox models adjusted for age, Auer rods and leukocyte counts. In conclusion, in this retrospective analysis, no difference with regard to clinical characteristics at diagnosis was found between AML patients whose leukemia cells show Axl expression vs patients whose cells are Axl negative. The association between Axl and bcl-2 and Axl and CD34 expression in de novo AML needs further investigation. Similarly, the negative impact of Axl levels on outcome should be confirmed in a larger cohort.
Introduction
Malignant transformation is a genetic multi-step process. Leukemias and lymphomas frequently arise on the background of specific chromosomal translocations leading either to expression of leukemia-specific fusion genes, such as the bcrabl gene, or inappropriate activation of normal genes under the influence of a different promotor region, such as bcl-2 (t14;18) or c-myc (t8;14) activation in certain lymphomas. Several leukemia-causing translocations have been discovered in recent years. However, these translocations may not be sufficient to cause the fully malignant disease, and other genetic hits may be necessary. For instance, in patients with t(8;21) positive acute myeloid leukemias (AML), t(8;21)-positive cells may be detected many years after obtaining complete remission (CR) without any sign for relapse. 1, 2 In addition, t(9;22)-positive cells may be found in the peripheral blood and bone marrow of normal, healthy individuals, 3 indicating that one single 'hit' may not be sufficient to give rise to leukemia. Other genetic lesions observed in AML probably are more important for the progression of the disease such as mutations of the ras genes. These lead to permanent activation of the p21
Ras -RAF signal transduction pathway. Rarely, mutations and deletions of the tumor suppressor genes p53 or p16 can be found in AML, respectively. 4, 5 Receptor tyrosine kinases (RTK) were first isolated in cancer cells of brain tumors, such as the receptor for the epidermal growth factor (EGF-R), and its homologue, c-erbB2/HER2-neu, which is associated with poor survival in ovarian and breast cancer. 6 Recently, a new class of RTKs has been discovered, termed the Axl/UFO/ark family. Axl was isolated from cells of two patients with chronic myelogeneous leukemia using gene transfection. 7, 8 Simultaneously, an identical gene was cloned from DNA of a patient with a myeloproliferative disorder and designated UFO (unknown functioning oncogene). 9 Soon, other members of this family were cloned, such as tyro-3 and c-mer. Genes of the Axl family are characterized by a specific extracellular structure: two immunoglobulin-like domains are expressed simultaneously with two fibronectin-type III domains. This structure is known from cellular adhesion molecules, and, in keeping with that, it was discovered that genes from the Axl family, namely ark, may play a role in cell adhesion. 10 The ligands isolated for some of these kinases suggested a yet unknown link to hemostasis. GAS6, a protein with sequence similarities to protein-S, was characterized as a ligand for Axl stimulating its tyrosine phosphorylation specifically. [11] [12] [13] [14] Axl is most abundantly expressed in cells of mesenchymal origin, such as osteoblasts, fibroblasts, and blood cells. 15 With regard to hematopoietic tissues, the strongest expression was found in cells of monocytic origin. In keeping with this, Axl also seemed to be correlated with monocytic lineage in leukemias. 16 In addition, RT-PCR results indicated that Axl may also be transcribed in immature, CD34-positive cells. 16 However, using the monoclonal antibody Axl-M50, strong co-expression of Axl and CD34 was found in only one of eight stem cell harvests. 17 Thus, although even normal hematopoietic cells express Axl, its role in myeloid leukemogenesis remains uncertain. To date, no systematic study exists to investigate the biological and clinical role of Axl-expression in AML.
In the present study, we asked whether the detection of Axl transcripts may be correlated with a specific phenotype in AML; in addition, we correlated Axl transcript numbers with CD34 and Bcl-2 expression, both of which have been associated with poor survival in AML. 18 Furthermore, we sought to investigate whether Axl-expressing AML may have a different outcome.
Materials and methods

Patients
Fifty-seven patients with de novo AML were considered for this study. These patients were taken from a larger cohort from the Swiss Group for Clinical Cancer Research (SAKK) of which RNA for molecular studies was available. The patients were treated in SAKK trial 30/85. 19 The treatment consisted of an induction chemotherapy composed of two induction cycles: one cycle with cytosin-arabinoside (100 mg/m The 57 patients with cryopreserved material available for the molecular biology study comprise 21% of the 276 patients accrued in the SAKK 30/85. Compared to the clinical study patients for whom no material could be evaluated, median age was slightly lower in the subgroup (43 vs 47 years), their white cell count was significantly higher and a somewhat higher number of patients with FAB M4 and M5 was observed. 20 Fifty-four out of these 57 samples had sufficient amounts of RNA. Patients characteristics are displayed in Table 1 .
Cells
Heparinized bone marrow (n = 4) and peripheral blood samples (n = 53) were obtained and mononuclear cells separated using Ficoll-gradient techniques. The median percent blasts in peripheral blood was 70%, and in bone marrow 90% with ranges 0-98% and 40-98%, respectively. Mononuclear cells were washed twice and RNA was then extracted as described. 20 
Reverse transcriptase polymerase chain reaction (RT-PCR)
Total RNA was isolated using guanidine thiocyanate/phenolcontaining RNAzol (Paesel and Lorei, Frankfurt, Germany), Table 1 Characteristics of AML patients whose samples were investigated in this study (1) 
HPLC analysis of PCR products
Twenty microliters from each PCR reaction were injected into a column packed with 2.5 mm diethylaminoethyl-bonded non-porous resin particles (DEAE-NPR No. N930-2656 from Perkin-Elmer Cetus) fixed to a Solvent Delivery System (Model 2700) associated with a High Pressure Liquid Chromatography (HPLC) system Interface, a UV/VIS monitor (model 1706), an HPLC automatic sampling system (model AS100T), a computer and corresponding software (Bio-Rad Laboratories, Hercules, CA, USA). One column could analyze up to 3000 samples if protected by a guard-column (5 mm) and a nylon membrane filter (0.45 mm) (Perkin-Elmer Cetus). The mobile phase was made of buffer A (25 mM Tris-HCl pH 9.0) and buffer B (25 mM Tris-HCl pH 9.0 and 1 M NaCl) with the following gradient program (time in minutes -% buffer A/% buffer B): 0.01 -70/30, 0.10 -60/40, 3.00 -48/52, 6.50 -28.4/71.6, 6.51 -0/100, 7.90 -0/100 and 8.00 -70/30 for 2 min to re-equilibrate the column. The total flow rate was 1 ml/min. The HPLC analysis translated the amount of PCR product into an area under the curve (AUC). In our hands, typically 30 ng of a 200-300 bp long PCR product is represented by an AUC of 10 000 arbitrary units, using this technique. 21 An AUC of around 1000-2000 was the lower limit of detection provided by this HPLC analysis system.
The results were interpreted as follows: the relative level of transcription of the target gene is expressed as a ratio of two areas, the AUC from the mRNA of interest (Axl bcl-2) against the AUC from ␤-actin mRNA. The results obtained are given as a ratio (× 10-3) using the formula published previously. 21 All analyses were performed with the investigators unaware of the patients' characteristics and outcome.
Flow cytometric analysis of CD34 expression
The number of CD34-expressing leukemia cells was determined using a standard dual-color direct immunofluorescence flow cytometry assay as described. 22 
Statistical procedures
Due to the high number of zero values, Axl expression was analyzed both qualitatively (presence or absence of expression) and quantitatively (level of expression). The levels and presence of Axl expression were compared between levels of clinical and prognostic factors with the Wilcoxon or the Fisher's exact test, where appropriate. Correlation with baseline quantitative parameters was analyzed with Spearmann rank correlation. 23 Association with response achievement was investigated with multivariate logistic regression. 24 Progression-free (PFS) and overall survival (OS) were calculated from date of diagnosis. Estimation of PFS and OS probabilities was performed with the Kaplan-Meier method 25 and distributions were compared using the logrank test. 26 The association with PFS and OS was analyzed using the Cox proportional hazard model. 27 A likelihood ratio test was used as an indicator of the overall significance of a marker (bcl-2, CD34 and Axl) in addition to the model including only clinical variables. 28 Hazard ratios (HR, with 95% CI and P values) smaller than 1 indicate a reduced risk of event (progression or death) as compared with the appropriate reference group. All P values were derived from two-sided tests of significance.
Results
Optimization of RT-PCR techniques
For determination of Axl mRNA expression, a RT-PCR assay was employed, since in this retrospective study, no viable cells were available for flow cytometric analysis. Also, due to lack of cell lysates no Western blotting could be performed. In addition, RT-PCR has been proven to be a reliable measure of Axl expression. 16, 17 In order to obtain information about Axl transcript numbers in a high number of de novo AML cases, we first modified our RT-PCR protocol such that quantitation could be performed (see Materials and methods).
After having established this protocol, RNA samples of 57 cases with AML were investigated. Of these, 54 samples proved to have sufficient amounts of RNA (ie good amplification of the reference gene). For this analysis, the level of expression of the reference cell line, K562, was arbitrarily set to a value of 1.0. All reactions were thus related to this expression level.
Axl expression in AML
Nineteen of 54 samples (35%) showed Axl transcripts. Two samples showed very high Axl-transcript numbers (ie Ͼ2), whereas the majority of the 19 samples revealed relatively low Axl expression (median: 0.35, range 0.03-2.39; see Figures 1  and 2 ). Comparing the clinical characteristics of patients with or without Axl expression, no difference was detected with regard to a number of parameters including morphology, number of leukocytes and Auer rods ( Table 2 ). In addition, extramedullary disease was not associated with presence vs Figure 1 Correlation between CD34 positivity in de novo AML and expression of the receptor tyrosine kinase Axl in 38 patients with AML. This analysis revealed a significant correlation between expression of CD34 and Axl (Spearman rank correlation, r = 0.42; P = 0.008). CD34 was determined using routine flow cytometry, Axl expression was determined as described in the Materials and methods section. The plot shows that there may be two different populations of CD34-positive cells, one of which seems to express Axl (lower right), the other of which was Axl negative (upper left).
Figure 2
Correlation between expression of the anti-apoptotic Bcl-2 proto-oncogene and Axl in 54 patients with AML. For this analysis, both Bcl-2 and Axl expression were determined using RT-PCR analysis. The Figure suggests a weak correlation between the expression of the two oncogenes in patients with AML (Spearman rank correlation, r = 0.32; P = 0.02).
absence of Axl expression. However, in the 19 patients positive for Axl expression, Axl expression levels were higher when extramedullary disease was present than in Axl-expressing leukemias with medullary disease only (median: 0.85 vs 0.16, respectively, P = 0.05).
Correlation of Axl expression with CD34 and Bcl-2
It has previously been shown that Axl may be expressed on a fraction of CD34-positive, hematopoietic progenitor cells. We thus asked whether detection of Axl transcripts was associated with expression of the progenitor cell marker, CD34, as determined by flow cytometric analysis. Thirty-eight samples had both determinations. The data obtained revealed a positive correlation between the level of Axl transcription and percent of cells positive for CD34 (n = 38, r = 0.42; P = 0.008; Figure 1 ). Upon more thorough analysis there seemed to be two different kinds of AML cells expressing CD34: one population with very high CD34 expression lacked Axl transcripts at all, whereas another population of AML cells revealed coexpression of CD34 and Axl. Therefore, there may be different subgroups of hematopoietic progenitor cells with regard to their expression of Axl ( Figure 1 ). We also asked whether the known oncogene, bcl-2, which plays a prognostic role in de novo AML, may be associated with the RTK Axl. We therefore compared the level of Axl expression and that of Bcl-2 expression (all 54 samples). There was a minor correlation between Axl and bcl-2, as determined by RT-PCR (n = 54, r = 0.32; P = 0.02; Figure 2 ).
Axl and response to treatment and outcome
Of the 19 patients whose blasts expressed Axl, 12 obtained a CR, whereas seven did not. In the Axl-negative patients, 26 out of 35 patients went into CR, whereas nine did not respond (NS, Table 2 ). When the values of individuals were correlated with treatment response, a trend towards higher expression was detected in non-responders, although this difference was not statistically significant (mean Axl-value in responders 0.22 vs 0.33 in non-responders; Table 2 ). When adjusting for clinically relevant covariates predictive for CR identified in the main study (sex, age and Auer rods) Axl expression did not show any significant contribution (␤: −0.695, P = 0.31).
We next sought to investigate whether Axl expression was associated with prognosis in AML. First, Axl expression was correlated with progression-free survival (PFS, 40 events, Figure 3) . Univariate hazard ratio (HR) calculation indicated that Axl-positive patients showed no significantly increased risk of progression (HR = 1.29; 95% confidence interval: 0.68-2.46). The independence of qualitative and quantitative Axl expression on PFS was evaluated using the Cox proportional hazards model in the presence of age, Auer rods and leukocyte counts. The likelihood ratio test showed a significant contribution of Axl levels over the set of clinical variables, and the estimated coefficient was 0.68 (s.e.: 0.28; P = 0.015; Table  3a ). Bcl-2 contribution was not significant (adjusting for age, auerrods, leukocyte counts ± Axl). In the subgroup with concomitant CD34 and Axl determination (n = 38, 28 events), quantitative Axl expression retained its prognostic relevance for PFS (estimated ␤: 0.71, s.e.: 0.29, P = 0.016) while CD34 did not show any significant contribution.
Next, the two groups were analyzed with regard to overall survival. Here too, patients whose cells were Axl positive were at slightly increased risk of death: 23 of 35 patients without Axl expression died (median OS 2.3 years) in comparison with 14 of 19 Axl-positive patients (median OS 1.6 years, Figure  4 ). Univariate hazard ratio for patients whose cells expressed Axl vs patients whose cells did not express Axl was estimated as 1.47 (95% CI: 0.66-3.27). The independence of qualitative and quantitative Axl expression on OS was evaluated using the Cox proportional hazards model in the presence of age, Auer rods and leukocyte counts. The likelihood ratio test showed a borderline significant contribution of Axl levels over the set of clinical variables, and the estimated coefficient was 0.61 (s.e. 0.31, P = 0.05; Table 3b ). Bcl-2 contribution for OS was not significant (adjusting for age, Auer rods and leukocyte counts). In the subgroup with concomitant CD34 and Axl determination, quantitative axl retained its prognostic relevance for PFS (estimated ␤: 0.73, P = 0.04) while CD34 did not show a significant contribution.
Since the association between Axl and worse outcome may be confounded by other genes causing poor prognosis in AML, such as the resistance genes MDR and MRP, or topoisomerase II, we looked for an association between expression of Axl, MDR, MRP, and topoisomerase II, each gene analyzed
Figure 3
Progression-free survival (PFS) in patients with AML and with or without Axl expression as determined using RT-PCR (see Materials and methods). For this analysis, Axl was either considered as negative (Axl value = 0) or positive (Axl value Ͼ0). Kaplan-Meier estimation is shown. There was no significant PFS difference with regard to expression of Axl (40 events, logrank P = 0.43). Nine patients had BMT, four negative Axl and five positive Axl and their PFS includes this additional treatment. 
Figure 4
Kaplan-Meier analysis of overall survival with regard to patients whose AML cells expressed Axl vs patients whose cells did not express Axl. Logrank analysis showed no difference between the two groups (P = 0.55).
by RT-PCR. However, there was no correlation between axl and MDR, MRP, or topoisomerase II (data not shown).
Since the worse outcome of Axl-positive AML may be explained by the two different treatment arms in post-induction chemotherapy, we asked whether Axl expression was associated with either arm of the study. However, there was no association between Axl and the different treatment arms (data not shown).
Discussion
Axl, as other RTKs, transforms cells by overexpression, not by gene mutation. [7] [8] [9] 29 Thus, overexpression was analyzed to investigate the role of a given RTK in certain tumors. Analysis may best be performed on the protein level, ie using Western blotting or flow cytometric analysis. However, due to the retrospective nature of this study, no viable cells were available for such studies. Since in previous studies, a good correlation between Axl transcript number and protein expression was found (Ref. 17 and AN, unpublished observations), a quantitative RT-PCR assay was used to determine the level of Axl transcript number in AML, and to correlate these data with clinical, biological and outcome data.
This study shows no difference between patients whose AML cells express Axl and those whose cells do not with regard to patient characteristics at diagnosis such as age, morphology, or extramedullary disease, although in the subgroup of patients positive for Axl expression, its levels were higher in patients with extramedullary disease. Given that Axl is highly expressed in normal, activated monocytes/macrophages, it is intriguing that no correlation with M4/M5 morphology was detected. Since Axl may also be expressed in immature hematopoietic cells, Axl expression in leukemia cells may rather reflect its expression in immature cells. This is also underscored by the correlation between Axl transcript numbers and percentage of cells expressing the hematopoietic differentiation antigen, CD34. AML cells expressing CD34 were more likely to show higher Axl transcript numbers (Figure 1) . At detailed analysis, it appeared that two different patterns of AML with high expression of CD34 might be observed: one group of CD34-positive AML with very high CD34 expression does not show a co-expression of Axl, whereas the other, somewhat lower CD34-positive AML expresses both CD34 and Axl (Figure 1) . Interestingly, by analysis of stem cell harvests with multiparameter flow cytometry, a co-expression of CD34 and Axl was observed only in a minority of stem cell harvests, indicating that there may be different hematopoietic progenitor populations. 17 Further studies are needed in order to define the role of Axl in CD34-positive progenitor cells.
We also studied the correlation between transcript numbers of Axl and expression of another oncogene, Bcl-2. Bcl-2 expression has been associated with poor prognosis and also a more immature phenotype in AML. 18, 20 Again, since no vital cells were available for this analysis, we determined bcl-2 expression using RT-PCR. As shown for CD34, bcl-2 was also associated with Axl expression in AML. Bcl-2 is a protein implicated in inhibiting apoptotic cell death in different cell systems. Bcl-2 interacts with its pro-apoptotic homologue, Bax, and recent data indicate that Bcl-2 inhibits apoptosis even in cells in which cytochrome-c has been released. 30 Axl, together with its ligand, GAS-6, has been implicated in blocking apoptosis in certain cell systems. In NIH 3T3 cells, expression of Axl together with supplementation of GAS-6 led to blockage of apoptosis. 31 From this, it would thus emerge that only the presence of the two proteins, Axl and GAS-6, may yield an inhibition of apoptosis. In the present study, we have not investigated expression of GAS-6 in leukemic cells. However, preliminary data obtained in a different set of patients indicate that Axl and GAS-6 are very rarely expressed simultaneously in the same sample (MS and AN, unpublished observations), thus making an autocrine loop in AML unlikely. Instead, expression of Bcl-2 may compensate for lack of GAS-6 such that activation of Axl may allow a growth advantage of the leukemic cells. However, this needs to be corroborated in well-defined systems.
Given that both Bcl-2 and CD34 expression have been linked to poor survival in AML, 18, 20 we next sought to analyze response and survival data of the patients with regard to Axl transcript expression. For this analysis, Axl was first considered either positive or negative. In the 19 patients with Axl expression, no significantly different response to chemotherapy was observed when they were compared to the 35 Axl-negative patients although the latter group had a somewhat higher response rate (74 vs 63%, Table 2 ). Similarly, when Axl expression was considered quantitatively, a nonsignificant trend towards lower expression of the gene was observed in patients going into complete remission after chemotherapy (0.22 vs 0.33, Table 2 ). Progression-free and overall survival were also shorter in leukemias expressing the Axl oncogene compared to Axl-negative patients, although this difference was statistically not significant ( Figures 3, 4) . These univariate analyses were in contrast to a multivariate analysis. When performing multivariate Cox analysis adjusted for age, Auer rods and leukocyte counts, quantitative Axl expression was an independent predictor of both progressionfree and overall survival, with higher transcript quantities conveying an increased risk for both progression and death. Although the number of samples analyzed was relatively small and our data should not be overinterpreted, the results of the multivariate analysis as well as the several trends described above suggest a certain role of Axl in the prognosis of AML. This may also not be explained by a positive association between Axl and MDR, as we could not find any correlation between these two genes. Whether the here described association between Axl expression and worse outcome is caused by an unknown linkage of Axl to certain poor cytogenetic risk factors, such as monosomies 5 or 7, is unclear. In the present study, only a small group of patients was analyzed for karyotypic analysis. Thus, we were unable to assess this certainly interesting question with this cohort of patients. However, we have analyzed this question in an ongoing multicenter trial, and were not able to find any association between Axl transcript numbers and poor cytogenetic features (MS and AN, unpublished observation). Thus, Axl itself may be linked to poor outcome in AML.
Several oncogene alterations, such as gene mutations, gene translocations and gene amplifications have been associated with different outcome in cancer patients. With respect to RTKs, gene amplification/expression of the tyrosine kinase EGF-R and c-erbB2 have been implicated with poor prognosis in solid tumors, such as breast and ovarian cancer, respectively. 6 To definitively address the question whether response to treatment and outcome may be different in AML patients whose cells express Axl compared to those whose cells do not, larger cohorts of patient with AML treated with welldefined chemotherapy regimens need to be prospectively investigated.
